Zobrazeno 1 - 10
of 44
pro vyhledávání: '"David A Soergel"'
Autor:
Shibu Yooseph, Granger Sutton, Douglas B Rusch, Aaron L Halpern, Shannon J Williamson, Karin Remington, Jonathan A Eisen, Karla B Heidelberg, Gerard Manning, Weizhong Li, Lukasz Jaroszewski, Piotr Cieplak, Christopher S Miller, Huiying Li, Susan T Mashiyama, Marcin P Joachimiak, Christopher van Belle, John-Marc Chandonia, David A Soergel, Yufeng Zhai, Kannan Natarajan, Shaun Lee, Benjamin J Raphael, Vineet Bafna, Robert Friedman, Steven E Brenner, Adam Godzik, David Eisenberg, Jack E Dixon, Susan S Taylor, Robert L Strausberg, Marvin Frazier, J Craig Venter
Publikováno v:
PLoS Biology, Vol 5, Iss 3, p e16 (2007)
Metagenomics projects based on shotgun sequencing of populations of micro-organisms yield insight into protein families. We used sequence similarity clustering to explore proteins with a comprehensive dataset consisting of sequences from available da
Externí odkaz:
https://doaj.org/article/d3c8becc5a9947e1bccad4901b6de6ec
Autor:
David G. Soergel, Kimberly A. Ramos, Ian E. James, Michael J. Fossler, Dennis Ruff, Franck Skobieranda
Publikováno v:
Clinical Pharmacology in Drug Development. 11:51-62
TRV734, an oral G-protein biased ligand at the μ-opioid receptor has demonstrated differentiated pharmacology in preclinical studies compared to unbiased ligands. First-time-in-human data suggested that TRV734 was safe and well tolerated and caused
Autor:
Neil Singla, David G. Soergel, David A. Burt, Eugene R. Viscusi, Monica Y Salamea, Mark A. Demitrack, Franck Skobieranda
Publikováno v:
Pain Practice. 19:715-731
OBJECTIVES The clinical utility of conventional IV opioids is limited by the occurrence of opioid-related adverse events. Oliceridine is a novel G protein-biased μ-opioid receptor agonist designed to provide analgesia with an improved safety and tol
Autor:
David A. Burt, Neil Singla, David G. Soergel, Emily Cook, Eugene R. Viscusi, Franck Skobieranda
Publikováno v:
Journal of Pain Research
Eugene R Viscusi,1 Franck Skobieranda,2 David G Soergel,2 Emily Cook,2 David A Burt,2 Neil Singla3 1Department of Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA; 2Trevena Inc., Chesterbrook, PA, US
Autor:
Brian M. Sadler, Franck Skobieranda, Maria Pitsiu, Colm Farrell, Michael J. Fossler, David A. Burt, David G. Soergel
Publikováno v:
The Journal of Clinical Pharmacology. 58:762-770
Oliceridine is a novel G protein-biased ligand at the μ-opioid receptor that differentially activates G protein coupling while mitigating β-arrestin recruitment. Unlike morphine, oliceridine has no known active metabolites; therefore, analgesic eff
Autor:
David G. Soergel, Piotr Ponikowski, Gerasimos Filippatos, Javed Butler, Sean P. Collins, Phillip D. Levy, Kathleen Goin, Adriaan A. Voors, G. Michael Felker, Gad Cotter, Stefanie Senger, Beth A. Davison, John R. Teerlink, Peter S. Pang, Justin A. Ezekowitz, David Bharucha, Marco Metra
Publikováno v:
Clinical Research in Cardiology, 107(2), 170-181. SPRINGER HEIDELBERG
Introduction TRV027, a 'biased' ligand of the angiotensin II type 1 receptor (AT1R), did not affect a composite clinical outcome at 30 days in a phase 2b acute heart failure (AHF) trial (BLAST-AHF).Methods Post-hoc analyses from BLAST-AHF (n = 618) e
Autor:
Ruth Ann Subach, David G. Soergel, Harold S. Minkowitz, Neil Singla, David A. Burt, Michael J. Fossler, Monica Y Salamea, Franck Skobieranda
Publikováno v:
Journal of Pain Research
Neil Singla,1 Harold S Minkowitz,2 David G Soergel,3 David A Burt,3 Ruth Ann Subach,3 Monica Y Salamea,3 Michael J Fossler,3 Franck Skobieranda3 1Lotus Clinical Research, Pasadena, CA, 2Memorial Hermann Memorial City Medical Center, Houston, TX, 3Tre
Autor:
Kathleen Goin, Gerasimos Filippatos, David G. Soergel, Sean P. Collins, Phillip D. Levy, David Bharucha, Gad Cotter, Beth A. Davison, Piotr Ponikowski, John R. Teerlink, Marco Metra, Peter S. Pang, Javed Butler, Adriaan A. Voors, G. Michael Felker, Justin A. Ezekowitz
Publikováno v:
European heart journal, vol 38, iss 30
European Heart Journal, 38(30), 2364-2373. Oxford University Press
European Heart Journal, 38(30), 2364-2373. Oxford University Press
Aims: Currently, no acute heart failure (AHF) therapy definitively improves outcomes. Reducing morbidity and mortality from acute heart failure (AHF) remains an unmet need. TRV027 is a novel ` biased' ligand of the angiotensin II type 1 receptor (AT1
Autor:
Brendt Stier, Charlotte A. Baidoo, Jerry Snidow, Steven Thornton, Marcy Powell, David G. Soergel, Guillermo J. Valenzuela, Linda M. Clayton, Timothy H. Montague, Michael J. Fossler
Publikováno v:
British Journal of Clinical Pharmacology. 83:2283-2291
Aims To investigate maternal, fetal, and neonatal safety and tolerability, pharmacodynamics, and pharmacokinetics of intravenous (IV) retosiban in pregnant women with spontaneous preterm labour (PTL) between 340/7 and 356/7 weeks’ gestation. Method
Autor:
Marco Metra, Peter S. Pang, Sean P. Collins, Justin A. Ezekowitz, Gerasimos Filippatos, Adriaan A. Voors, G. Michael Felker, Beth A. Davison, John R. Teerlink, Phillip D. Levy, Javed Butler, Stefanie Senger, Piotr Ponikowski, Gad Cotter, Rayan Jo Rachwan, Rudolf A. de Boer, David G. Soergel
Publikováno v:
European Journal of Heart Failure, 21(12), 1561-1570. Wiley
Aims Neurohormonal activation characterizes chronic heart failure (HF) and is a well-established therapeutic target. Neurohormonal activation may also play a key role in acute HF (AHF). We aim to describe the association between plasma renin activity